On July 17, China Life Insurance declined 3.18% in regular trading, trading at HK$26.78/share, with turnover of HK$676 million.

The decline was driven by broad weakness across the insurance sector and profit-taking following the stock's 4%-plus surge on July 15 when it rallied on a blockbuster earnings pre-announcement. Peer stocks also fell, with NCI down 3.97%, Sunshine Insurance down 3.12%, and China Taiping down 2.16%, reflecting significant sector linkage.

China Life had disclosed on July 14 that it expects H1 attributable profit of RMB 128.9 billion to RMB 137.1 billion, representing 215% to 235% year-over-year growth, primarily driven by strong investment returns amid the Q2 equity market rally and FVTPL accounting amplification. While UBS reiterated its Buy rating with a HK$40 target price on July 17, the market remains divided on whether investment-driven profit growth is sustainable, triggering a classic buy-the-rumor-sell-the-news pattern.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)